Hexalen Related Published Studies
Well-designed clinical trials related to Hexalen (Altretamine)
The bioavailability of three altretamine formulations. [1989.12.15]
Well-designed clinical trials possibly related to Hexalen (Altretamine)
Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. [1996.02.15]
The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial. [1995.06]
A randomized clinical trial in bronchogenic small-cell carcinoma evaluating alternating maintenance therapy of vincristine, adriamycin, procarbazine, and etoposide (VAPE) with cyclophosphamide, CCNU, and methotrexate (CCM) versus CCM maintenance alone in complete responders following VAPE induction and late intensification. [1994.12]
[Treatment of cancers of the ovary. Phase II trial of increase of the dose of cisplatin] [1993.01.30]
Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute. [1992.02]
Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. [1992]
Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. [1991.07]
Hexamethylmelamine for the treatment of ovarian cancer--the Mount Sinai experience. [1991.03]
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. [1991]
Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. [1990.10.15]
A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. [1990.02]
A randomized study of sequential versus alternating combination chemotherapy in advanced ovarian carcinoma. [1990]
A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. [1989.08]
Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma. [1989]
Carboplatin in combination therapy for ovarian cancer. [1988.06]
Other research related to Hexalen (Altretamine)
Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. [2004.03]
Oral altretamine used as salvage therapy in recurrent ovarian cancer. [2004.01]
Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study. [2003.02]
A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer. [2001.08]
Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). [2001.08]
Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer. [2001.02]
Altretamine for the treatment of metastatic renal cell carcinoma. A Hoosier Oncology Group trial. [2001]
[Combination chemotherapy with hexamethylamine (Hexalen, Altretamine, Hexastat) and sarcolysine in advanced ovarian carcinoma] [2000]
Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. [1998.06]
Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. [1997.01]
Phase II evaluation of altretamine for advanced or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. [1996.07]
Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer. [1996]
Clinical pharmacokinetics of altretamine. [1995.06]
Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy. [1995.06]
Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma. [1993.10]
A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer. [1991.03]
Analysis of prognostic factors and survival in patients with ovarian cancer treated with second-line hexamethylmelamine (altretamine). [1991.03]
Altretamine. [1991.02]
Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary. [1989.05]
Other possibly related research studies
Recurrent ovarian cancer: how important is it to treat to disease progression? [2004.11.15]
Comparative study on three chemotherapeutic regimens for the treatment of advanced epithelial ovarian cancer. [2000]
Solvent, emulsifier and drug concentration factors in poly(D,L-lactic acid) microspheres containing hexamethylmelamine. [2002.01]
Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. [2001.04]
Paclitaxel, carboplatin, and hexamethyl-melamine (taxchex) as first-line therapy for ovarian cancer. [1999.11]
Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature. [1997.07]
Evaluation of the porphyrinogenic risk of antineoplastics. [1997.05]
N-(Hydroxymethyl) melamines. [1997.02]
[Chemotherapy for recurrent ovarian cancer] [1996.08]
The activity of N-(hydroxymethyl) melamines in fresh human ovarian tumour cells and xenografts. [1996.07]
A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma. [1995.10]
Carboplatin (CBDCA)-hexamethylmelamine (HMM)-oral etoposide (VP-16) first-line treatment of ovarian cancer patients with bulky disease: a phase II study. [1995.07]
Oral therapy for small cell lung cancer. [1995.06]
Antitumor activity of hexamethylmelamine on human tumor xenografts serially transplanted in nude mice. [1994.11]
Advances in the chemotherapy of gynecologic cancer. [1994.09]
A Bayesian analysis of institutional effects in a multicenter cancer clinical trial. [1994.03]
Prodrugs of hydroxymethylpentamethylmelamine: a principal active metabolite of the antineoplastic agent hexamethylmelamine. [1994.02]
Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. [1993.11.03]
Second-line chemotherapy for recurrent carcinoma of the ovary. [1993.02.15]
Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. [1992.12]
Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer. [1992.11]
Role of chemotherapy in the future treatment of ovarian cancer. [1992]
Advances in the chemotherapy of gynecologic malignancies. [1992.01]
Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer. [1991.09]
[Iliac-ureteral fistula as a complication of multimodal treatment of bladder carcinoma] [1991.07]
Hexamethylmelamine: activity in lymphoma and other tumors. [1991.03]
The role of hexamethylmelamine in the management of ovarian cancer. [1991.03]
Hexamethylmelamine: pharmacology and mechanism of action. [1991.03]
Subrenal capsule assay in selection of chemotherapy after operation for recurrent ovarian cancer. [1991.01]
Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement. [1990.12]
The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP). [1990.10]
Selecting drug combinations based on total equivalent dose (dose intensity) [1990.09.19]
Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center. [1990]
Hexamethylmelamine as a single second-line agent in ovarian cancer. [1990.01]
Phase I and clinical pharmacological evaluation of a parenteral hexamethylmelamine formulation. [1990.01.01]
Schedule and dosage modification of a cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin combination chemotherapy regimen for refractory ovarian cancer. [1989.09]
Concurrent chemotherapy and single high-dose plus whole abdominopelvic radiation for persistent ovarian carcinoma. [1989.08]
Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. [1989.08.01]
Phase II evaluation of peroral carmofur, cyclophosphamide, and hexamethylmelamine as a second-line therapy in advanced epithelial ovarian carcinoma. [1989.07]
Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin ovarian cancer regimen. [1989.03]
Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion. [1989]
[Scintigraphic follow-up of osteosarcoma during neoadjuvant chemotherapy. Results of the cooperative osteosarcoma study of the Society for Pediatric Oncology] [1988.12]
Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group. [1988.11]
Advanced carcinoma of the ovary with central nervous system relapse. [1988.07]
The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis. [1988.07]
Combined effects of host antitumor immune responses and chemotherapy. Studies with hexamethylmelamine. [1988.06]
An interaction between cytostatic and anticonvulsant drugs. [1988.04]
Chemotherapeutic and surgical induction of pathological complete remission and whole abdominal irradiation for consolidation does not enhance the cure of stage III ovarian carcinoma. [1988.03]
Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. [1988.02]
The role of cytoreduction in ovarian cancer. [1988]
The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer. [1987.12]
Cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin combination chemotherapy in mixed mesodermal sarcoma of the female genital tract. [1987.08]
Topotecan: weighing in when there are many options. [2005.10]
Recent advances in the treatment of epithelial ovarian cancer. [2001.09]
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. [2001]
Salvage therapy for ovarian cancer. [1999.09]
Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patients. [1999]
The effect of reimbursement policies on the management of Medicare patients with refractory ovarian cancer. [1999.02]
Treatment of refractory and recurrent ovarian cancer. [1999.02]
Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. [1994.11]
Gynecologic malignancies. [1993]
Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy. [1992.10]
Hypersensitivity reactions. [1992.10]
Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. [2006.03.20]
[Study of vinorelbine (V) combined with hexamethylmelamine (H) (combination V-H) in adenocarcinoma of the ovary: results a phase I-IIA trial, NHO-88, of ARTAC "ovarian" group] [1991]
Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)). [1990.09]
|
